Increasing awareness, participation, funding and streamlining communication for MS trials.
3rd December, 2013
Clinical research does not end with the completion of the phase III clinical trials required for the registration and availability of a new drug by
10th September, 2013
The last decade, indeed the last year, has seen the introduction of several new disease-modifying drugs for people with relapsing remitting MS. As people with